UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000002879 |
|---|---|
| Receipt number | R000003455 |
| Scientific Title | Phase I study of pegylated liposomal doxorubicin (PLD) in combination with docetaxel (TXT) in recurrent or refractory ovarian cancer (epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma) |
| Date of disclosure of the study information | 2009/12/12 |
| Last modified on | 2020/08/10 14:23:21 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2009/12/11 15:32:05 | ||
| 2 | Update | 2010/01/05 17:09:11 | Condition Narrative objectives1 Primary outcomes Key secondary outcomes |
|
| 3 | Update | 2010/01/05 17:12:49 | Public title |
|
| 4 | Update | 2010/01/06 14:20:38 | Key inclusion criteria Key exclusion criteria |
|
| 5 | Update | 2010/01/06 14:23:50 | Gender |
|
| 6 | Update | 2011/06/24 14:25:20 | Name of person sending information Organization Division name Address Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
| 7 | Update | 2011/06/24 14:27:02 | Recruitment status |
|
| 8 | Update | 2015/04/14 17:53:40 | TEL TEL Email1 |
|
| 9 | Update | 2015/12/11 14:01:17 | Publication of results Results |
|
| 10 | Update | 2016/04/14 14:10:57 | Name of primary person or sponsor Organization Co-sponsor Co-sponsor Name of secondary funder(s) Name of secondary funder(s) Institutions |
|
| 11 | Update | 2017/09/04 07:26:52 | Recruitment status |
|
| 12 | Update | 2019/05/10 11:45:35 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 13 | Update | 2019/12/31 11:29:55 | Date of IRB |
|
| 14 | Update | 2020/08/10 14:23:21 | URL releasing protocol URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures Plan to share IPD IPD sharing Plan description |
